研究单位：[1]The Affiliated Hospital of Qingdao University[2]Shandong Cancer Hospital Affiliated to Shandong First Medical University[3]Chinese PLA General Hospital[4]Zibo Central Hospital[5]Affiliated Cancer Hospital & Institute of Guangzhou Medical University[6]Jinan Central Hospital[7]Qilu Hospital of Shandong University[8]Yantai Yuhuangding Hospital[9]Nanfang Hospital, Southern Medical University[10]Provincial Hospital Affiliated to Shandong First Medical University[11]The First Affiliated Hospital of Nanchang University[12]The Fourth Hospital of Hebei Medical University[13]Peking University Cancer Hospital & Institute[14]Peking University People's Hospital[15]Tianjin Cancer Hospital[16]First Affiliated Hospital of Xi 'an Jiaotong University[17]Union Hospital of Huazhong University of Science and Technology[18]Wuhan University[19]Brigham and Women's Hospital[20]The Second Xiangya College of Central South University[21]Weihai Municipal Hospital[22]Mountain University Cancer Hospital[23]Ruijin Hospital
The goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving the 5-year overall survival rate and decrease the peritoneal metastases rate of patients with advanced gastric cancer underwent Laparoscopic Gastrectomy with D2 Lymphadenectomy. Participants will be divided into two groups, Experimental group received laparoscopic (robotic) D2 surgery plus HIPEC2 times plus systemic chemotherapy 6~8 cycles; and Control group received laparoscopic (robotic) D2 surgery plus systemic chemotherapy 6~8 cycles.
